According to the European guidelines beta bloquers and specialy nebivolol were able to reduce mortality but only HF hospitalizations in older patients. You can read about that in the following meta analysis.
The phisiological explanation might be the improvement of isovolumetric filling time and improvement of diastolic funtion.
One other recomendacion is the control of risk factors and arrhythmias like hipertension and atrial fibrillation. Here the beta bloquers can help specially in the AF.
Article Beta-blockers in heart failure with preserved ejection fract...
According to my knowledge BB ( partyculary nebivolol) are NOT worth in patients with HFpEF!
2016 ESC GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF ACUTE AND CHRONIC HEART FAILURE
I agree with opinion of Dr Hugo and Dr Irina. ESC guideline recommended diuretics, candesartan and beta blocker specially nevibolol in the management of heart failure with preserved ejection fraction. Antiarrhymic and vasodilator property of nevibolol might have some added benefit in this situation.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0090555
I am complitelly aggre with previous answer/ According to the evidence based medicine main indications for use nebivolol is pld patients with deduced EF. But we need future RCT for study nebivolol in HF with pEF.
My answer is yes. Nebivolol is a modern cardio selective beta 3 blocker. When the heart fails with preservation of systolic function, drugs in this class reduce tachycardia which adversely impacts diastolic function and by reducing tachycardia improve myocardial perfusion. It also causes myocardial hypertrophic regression which improves diastolic compliance and function. By its mechanism of function it is not adverse to systolic function while at the same time improves diastolic function
- Badges
- Science topic
- Similar topics
- Biological Science
- Physiology
- Physiological Processes
- Stress